Drugs that contain Lenvatinib Mesylate

1. List of Lenvima drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7253286 EISAI INC Nitrogen-containing aromatic derivatives
Oct, 2025

(2 years from now)

US7612208 EISAI INC Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
Sep, 2026

(3 years from now)

US11186547 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

US10407393 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

US10259791 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006256 EISAI INC Antitumor agent for thyroid cancer
Jul, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 15, 2025
New Indication (I) Aug 10, 2024
M Dec 19, 2024

Market Authorisation Date: 13 February, 2015

Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer

Dosage: CAPSULE;ORAL

How can I launch a generic of LENVIMA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in